Latin America Hip Fracture Mortality Study (LAMOS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to estimate the survival proportion one year after surgery for intertrochanteric fracture in older adults in Latin America.
Condition or disease
This is a multi-center, prospective, observational clinical study to evaluate mortality in patients with surgically-treated hip fracture in Latin America, and investigate associated prognostic factors. Patients will be followed for 12 months.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
60 Years to 110 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with surgically-treated hip fracture in Latin America
Adults 60 years and older
Diagnosis of an isolated intertrochanteric fracture (AO 31-A) confirmed by radiographic evaluation
Primary surgical fracture treatment within 10 days after trauma
No prior treatment for the fracture
Ability to understand the content of the patient information / informed consent form
Willingness and ability to participate in the clinical investigation according to the CIP
Signed and dated IRB/EC-approved written informed consent
Polytrauma (ie, multiple injuries, whereof one or the combination of several injuries is life threatening)
Pathologic fracture due to a disease other than osteoporosis (eg, tumor, metastasis)
Class 5 and 6 of the American Society of Anesthesiologists (ASA) physical status classification (Appendix 2)
Neurological and/or psychiatric disorders that would preclude reliable assessment (eg, Parkinson's disease, multiple sclerosis, severe depression)
Recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment
Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study